Clinical Trial: Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917117) titled 'Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors' on Oct. 22.

Brief Summary: Systemic treatments such as chemotherapy or monoclonal antibodies are an essential part of oncological treatment in breast cancer, which have demonstrated a survival benefit (1,2,3,4,5). This cancer is the most common cancer in women, being the cancer with the highest incidence worldwide (6), with an estimated 35,001 new cases in 2023 in Spain (7). This is why a large number of patients receive systemic treatments that help surgery and radiotherapy to achieve a cure of over 80% in our environment, with a 5-y...